Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Wang M.Y.,,Potentially Functional Polymorphisms in the CASP7 Gene Contribute to Gastric Adenocarcinoma Susceptibility in an Eastern Chinese Population,2013,PLoS ONE,10,10.1371/journal.pone.0074041,China;China,Article,Shanghai;Shanghai,1,Journal,2-s2.0-84883776928
Li Q.,,Polymorphisms in the mTOR Gene and Risk of Sporadic Prostate Cancer in an Eastern Chinese Population,2013,PLoS ONE,23,10.1371/journal.pone.0071968,China;China,Article,Shanghai;Shanghai,1,Journal,2-s2.0-84881095969
Xu M.,,A Polymorphism (rs2295080) in mTOR Promoter Region and Its Association with Gastric Cancer in a Chinese Population,2013,PLoS ONE,23,10.1371/journal.pone.0060080,China,Article,Nanjing,1,Journal,2-s2.0-84875525196
He J.,,Genetic variations of mTORC1 genes and risk of gastric cancer in an eastern chinese population,2013,Molecular Carcinogenesis,93,10.1002/mc.22013,China;China,Article,Shanghai;Shanghai,0,Journal,2-s2.0-84886296871
Zhu M.,,Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations,2013,Journal of Thoracic Oncology,20,10.1097/JTO.0b013e31828916c6,China,Article,Shanghai,1,Journal,2-s2.0-84879499990
Cao Q.,,A Functional Variant in the MTOR Promoter Modulates Its Expression and Is Associated with Renal Cell Cancer Risk,2012,PLoS ONE,36,10.1371/journal.pone.0050302,China,Article,Nanjing,1,Journal,2-s2.0-84870386863
He J.,,Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations,2012,Human Genetics,148,10.1007/s00439-012-1152-8,China;China,Article,Shanghai;Shanghai,0,Journal,2-s2.0-84862773697
Wang M.,,Potentially functional variants of PLCE1 identified by GWASs contribute to gastric adenocarcinoma susceptibility in an Eastern Chinese population,2012,PLoS ONE,46,10.1371/journal.pone.0031932,China,Article,Shanghai,1,Journal,2-s2.0-84863263031
PÃ³pulo H.,,The mTOR signalling pathway in human cancer,2012,International Journal of Molecular Sciences,407,10.3390/ijms13021886,Portugal,Review,Porto,1,Journal,2-s2.0-84857675728
Hanahan D.,,Hallmarks of cancer: The next generation,2011,Cell,30122,10.1016/j.cell.2011.02.013,United States;Switzerland,Review,San Francisco;Epalinges,1,Journal,2-s2.0-79952284127
Jemal A.,,Global cancer statistics,2011,CA Cancer Journal for Clinicians,27704,10.3322/caac.20107,United States,Article,Atlanta,1,Journal,2-s2.0-79952232216
Holm K.,,SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels,2010,BMC Bioinformatics,77,10.1186/1471-2105-11-600,Norway,Article,Oslo,1,Journal,2-s2.0-78650155713
Washington K.,,7th edition of the AJCC cancer staging manual: Stomach,2010,Annals of Surgical Oncology,742,10.1245/s10434-010-1362-z,United States,Editorial,Nashville,1,Journal,2-s2.0-78650993111
Sato T.,,Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer,2010,Oncogene,142,10.1038/onc.2010.28,Japan;United States,Article,Tokyo;Los Angeles,1,Journal,2-s2.0-77952243626
Wang X.,,"Rationales, design and recruitment of the Taizhou longitudinal study",2009,BMC Public Health,81,10.1186/1471-2458-9-223,China;China,Article,Shanghai;Taizhou,1,Journal,2-s2.0-68049137338
Coleman L.J.,,Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity,2009,British Journal of Cancer,91,10.1038/sj.bjc.6605044,United Kingdom;United Kingdom,Article,Leeds;Leeds,1,Journal,2-s2.0-65549108194
Noh W.C.,,Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables,2008,Breast Cancer Research and Treatment,63,10.1007/s10549-007-9746-x,South Korea,Article,Seoul,0,Journal,2-s2.0-46749148110
Baralle M.,,Influence of Friedreich Ataxia GAA Noncoding Repeat Expansions on Pre-mRNA Processing,2008,American Journal of Human Genetics,41,10.1016/j.ajhg.2008.06.018,Italy,Article,Trieste,1,Journal,2-s2.0-46149111652
Herberger B.,,Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma,2007,Clinical Cancer Research,80,10.1158/1078-0432.CCR-07-0738,Austria,Article,Vienna,1,Journal,2-s2.0-34548085100
Armengol G.,,"4E-binding protein 1: A key molecular ""funnel factor"" in human cancer with clinical implications",2007,Cancer Research,206,10.1158/0008-5472.CAN-07-0881,Spain,Review,Barcelona,1,Journal,2-s2.0-34548028705
Yang Q.,,Expanding mTOR signaling,2007,Cell Research,403,10.1038/cr.2007.64,United States,Review,Ann Arbor,1,Journal,2-s2.0-34547907805
Guertin D.,,Defining the Role of mTOR in Cancer,2007,Cancer Cell,2166,10.1016/j.ccr.2007.05.008,United States;United States,Review,Cambridge;Cambridge,1,Journal,2-s2.0-34347220473
Lang S.,,Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model,2007,International Journal of Cancer,140,10.1002/ijc.22442,Germany,Article,Regensburg,1,Journal,2-s2.0-33947099498
Robb V.A.,,Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma,2007,Journal of Urology,141,10.1016/j.juro.2006.08.076,United States,Article,Philadelphia,0,Journal,2-s2.0-33845309430
Patel P.,,Targeting von Hippel-Lindau pathway in renal cell carcinoma,2006,Clinical Cancer Research,139,10.1158/1078-0432.CCR-06-2254,United States,Article,New York,1,Journal,2-s2.0-33846203776
Faivre S.,,Current development of mTOR inhibitors as anticancer agents,2006,Nature Reviews Drug Discovery,784,10.1038/nrd2062,France,Review,Clichy,0,Journal,2-s2.0-33746637660
Shaw R.,,"Ras, PI(3)K and mTOR signalling controls tumour cell growth",2006,Nature,1513,10.1038/nature04869,United States,Review,San Diego,0,Journal,2-s2.0-33745307617
Sarbassov D.,,Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB,2006,Molecular Cell,1950,10.1016/j.molcel.2006.03.029,United States;United States,Article,Cambridge;Cambridge,1,Journal,2-s2.0-33646023695
Wullschleger S.,,TOR signaling in growth and metabolism,2006,Cell,4130,10.1016/j.cell.2006.01.016,Switzerland,Review,Basel,1,Journal,2-s2.0-32044465506
Bose S.,,The Akt pathway in human breast cancer: A tissue-array-based analysis,2006,Modern Pathology,153,10.1038/modpathol.3800525,United States;United States,Article,Los Angeles;Los Angeles,1,Journal,2-s2.0-30944442856
Faried L.S.,,Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy,2006,Oncology Reports,48,10.3892/or.16.1.57,Japan,Article,Maebashi,1,Journal,2-s2.0-33750742240
Dancey J.,,Therapeutic targets: MTOR and related pathways,2006,Cancer Biology and Therapy,162,10.4161/cbt.5.9.3175,United States,Review,Bethesda,1,Journal,2-s2.0-33751162384
Sarbassov D.,,Growing roles for the mTOR pathway,2005,Current Opinion in Cell Biology,1196,10.1016/j.ceb.2005.09.009,United States,Review,Cambridge,0,Journal,2-s2.0-27544500981
Guertin D.,,An expanding role for mTOR in cancer,2005,Trends in Molecular Medicine,423,10.1016/j.molmed.2005.06.007,United States,Article,Cambridge,0,Journal,2-s2.0-23144467910
Sahin F.,,mTOR and P70 S6 kinase expression in primary liver neoplasms,2004,Clinical Cancer Research,299,10.1158/1078-0432.CCR-04-0941,United States,Article,Baltimore,1,Journal,2-s2.0-11144236505
Dos D.,,"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton",2004,Current Biology,1869,10.1016/j.cub.2004.06.054,United States,Article,Cambridge,1,Journal,2-s2.0-3342895823
Wacholder S.,,Assessing the probability that a positive report is false: An approach for molecular epidemiology studies,2004,Journal of the National Cancer Institute,1274,10.1093/jnci/djh075,United States,Article,Bethesda,1,Journal,2-s2.0-1642295096
Bjornsti M.A.,,Lost in translation: Dysregulation of cap-dependent translation and cancer,2004,Cancer Cell,139,10.1016/j.ccr.2004.05.027,United States,Review,"Memphis TN,",1,Journal,2-s2.0-2942518250
Buratti E.,,Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: A functional link with disease penetrance [2],2004,American Journal of Human Genetics,142,10.1086/420978,Italy,Letter,Trieste,1,Journal,2-s2.0-2442676753
Fingar D.,,mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E,2004,Molecular and Cellular Biology,632,10.1128/MCB.24.1.200-216.2004,United States,Article,Boston,1,Journal,2-s2.0-0345732640
Huang S.,,Targeting mTOR signaling for cancer therapy,2003,Current Opinion in Pharmacology,376,10.1016/S1471-4892(03)00071-7,United States,Review,"Memphis TN,",0,Journal,2-s2.0-0041802820
Hohenberger P.,,Gastric cancer,2003,Lancet,525,10.1016/S0140-6736(03)13975-X,Germany,Conference Paper,Berlin,0,Journal,2-s2.0-0043200978
Giacopelli F.,,The first intron of the human osteopontin gene contains a C/EBP-beta-responsive enhancer,2003,Gene Expression,20,10.3727/000000003108748991,Italy,Article,Genoa,0,Journal,2-s2.0-0038045063
Kelley J.R.,,Gastric cancer epidemiology and risk factors,2003,Journal of Clinical Epidemiology,596,10.1016/S0895-4356(02)00534-6,,Article,,0,Journal,2-s2.0-0037263849
Saucier C.,,Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis,2002,Oncogene,55,10.1038/sj.onc.1205261,Canada,Article,Montreal,1,Journal,2-s2.0-85047700252
Vivanco I.,,The phosphatidylinositol 3-kinase-AKT pathway in humancancer,2002,Nature Reviews Cancer,4700,10.1038/nrc839,United States,Article,Los Angeles,0,Journal,2-s2.0-0036632368
Ritchie M.,,Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer,2001,American Journal of Human Genetics,1385,10.1086/321276,United States,Article,Nashville,1,Journal,2-s2.0-0034973569
Palli D.,,Epidemiology of gastric cancer: An evaluation of available evidence,2000,Journal of Gastroenterology,116,,Italy,Conference Paper,Florence,0,Journal,2-s2.0-0034056522
Keith C.T.,,"PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints",1995,Science,416,10.1126/science.270.5233.50,United States,Short Survey,Cambridge,0,Journal,2-s2.0-0028800996
